Andrew Brooks, Designer of COVID-19 Saliva Test, Dies at 51

The Rutgers University researcher created the first FDA-authorized spit test, which has since been used by millions of people.

Written byAmanda Heidt
| 3 min read
Obituary, obituaries, Rutgers university, COVID-19, SARS-CoV-2, coronavirus, pandemic, saliva, diagnostics, disease & medicine, saliva testing, techniques

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ABOVE: Andrew Brooks photographed in April 2020 at the RUCDR Infinite Biologics soon after the Rutgers COVID-19 saliva test received emergency approval from the FDA.
NICK ROMANENKO

Andrew Brooks, a molecular neuroscientist who developed the first COVID-19 saliva test to receive emergency use authorization by the US Food and Drug Administration, died on January 23 of a heart attack. He was 51.

In the early days of the pandemic, when testing resources such as swabs and reagents were scarce, Brooks’s saliva test offered a fast and reliable way to screen large numbers of people. The test, which he designed while head of the Rutgers-affiliated biorepository RUCDR Infinite Biologics, protected essential workers from exposure to the virus as they collected samples by doing away with the need for technicians to be on-hand to gather the fluid—people could simply spit into a cup. The FDA first authorized the test in April 2020, and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • amanda heidt

    Amanda first began dabbling in scicom as a master’s student studying marine science at Moss Landing Marine Labs, where she edited the student blog and interned at a local NPR station. She enjoyed that process of demystifying science so much that after receiving her degree in 2019, she went straight into a second master’s program in science communication at the University of California, Santa Cruz. Formerly an intern at The Scientist, Amanda joined the team as a staff reporter and editor in 2021 and oversaw the publication’s internship program, assigned and edited the Foundations, Scientist to Watch, and Short Lit columns, and contributed original reporting across the publication. Amanda’s stories often focus on issues of equity and representation in academia, and she brings this same commitment to DEI to the Science Writers Association of the Rocky Mountains and to the board of the National Association of Science Writers, which she has served on since 2022. She is currently based in the outdoor playground that is Moab, Utah. Read more of her work at www.amandaheidt.com.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies